Acadia Pharmaceuticals (ACAD) Change in Receivables (2013 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Change in Receivables of $13.9 million for Q1 2026, up 589.48% year-over-year from $2.0 million in Q1 2025, and up 147.78% quarter-over-quarter from $5.6 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Change in Receivables (2013 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Change in Receivables history runs 14 years deep, the most recent figure standing at $13.9 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 589.48% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $34.6 million (up 1234.21% YoY), while the FY2025 annual figure was $22.7 million, up 1112.92% from the prior year.
- Change in Receivables for Q1 2026 stood at $13.9 million, up from $5.6 million in the prior quarter.
- The five-year high for Change in Receivables was $35.2 million in Q4 2023, with the low at -$18.8 million in Q3 2023.
- The 5-year median for Change in Receivables is $3.4 million (2023), against an average of $4.4 million.
- Peak annual rise in Change in Receivables reached 7208.51% in 2023, while the deepest fall reached 351.99% in 2023.
- Acadia Pharmaceuticals' Change in Receivables stood at $482000.0 in 2022, then surged by 7208.51% to $35.2 million in 2023, then slumped by 117.59% to -$6.2 million in 2024, then jumped by 190.46% to $5.6 million in 2025, then jumped by 147.78% to $13.9 million in 2026.
- Business Quant data shows ACAD's Change in Receivables at $13.9 million in Q1 2026, $5.6 million in Q4 2025, and $8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 15.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.30 Mn |
| Jun 30, 2026 | 15.30 Mn |
| Mar 31, 2026 | 13.89 Mn |
| Mar 31, 2026 | 13.89 Mn |
| Dec 31, 2025 | 5.61 Mn |
| Dec 31, 2025 | 5.61 Mn |
| Sep 30, 2025 | 8.35 Mn |
| Sep 30, 2025 | 8.35 Mn |
| Jun 30, 2025 | 6.75 Mn |
| Jun 30, 2025 | 6.75 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | -6.20 Mn |
| Dec 31, 2024 | -6.20 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |